Nabulsi Azmi 4
4 · Phathom Pharmaceuticals, Inc. · Filed Jan 21, 2022
Insider Transaction Report
Form 4
Nabulsi Azmi
Chief Operating Officer
Transactions
- Award
Stock Option (Right to Buy)
2022-01-19+97,500→ 97,500 totalExercise: $15.21Exp: 2032-01-18→ Common Stock (97,500 underlying) - Award
Common Stock
2022-01-19+19,500→ 21,378 total
Holdings
- 765,700(indirect: By Trust)
Common Stock
- 843.42(indirect: By 401(k))
Common Stock
Footnotes (3)
- [F1]Represents restricted stock units ("RSUs") granted on January 19, 2022. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of January 19, 2022, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
- [F2]Includes 1,425 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2021 and January 2022 and 453 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan which were inadvertenly omitted from the most recent Form 4.
- [F3]The stock option will vest with respect to 25% of the shares of common stock on January 19, 2023, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.